Personalis - PSNL STOCK NEWS

Personalis, Inc. (NASDAQ: PSNL), a leader in cancer genomics, will present at the 24th Annual Needham Virtual Growth Conference on January 11, 2022. The company's innovative Personalis NeXT Platform® provides comprehensive genomic insights from tissue samples, aiding in precision oncology. Furthermore, Personalis is a key provider for Veterans Affairs' Million Veteran Program, reinforcing its position in population sequencing. The firm's lab emphasizes clinical accuracy with necessary certifications, ensuring top-tier service in advanced cancer diagnostics.

Personalis, Inc. (NASDAQ: PSNL) announced the launch of NeXT Personal, a next-generation tumor-informed liquid biopsy assay that enhances detection of molecular residual disease (MRD) with a sensitivity down to 1 part-per-million. This marks a 10- to 100-fold improvement over existing technologies, enabling earlier detection across various cancers, including challenging low mutational burden and early-stage cancers. NeXT Personal creates a tailored liquid biopsy panel from a patient’s tumor to better monitor cancer treatment.

Personalis, Inc. (NASDAQ: PSNL) announced participation in the 33rd Annual Piper Sandler Virtual Healthcare Conference on December 1, 2021. This event showcases Personalis' leadership in advanced cancer genomics aimed at precision cancer therapies. Interested parties can access a pre-recorded webcast of the presentation for 90 days through their website. Personalis’ NeXT Platform® supports comprehensive genomic insights from tissue samples, enhancing diagnostics for biopharmaceutical customers. For further details, visit investors.personalis.com.

Personalis, a leader in advanced cancer genomics, will participate in the Society for Immunotherapy of Cancer Annual Meeting from November 12-14. The company will present online exhibits, including the Personalis NeXT Platform for comprehensive tumor and immune microenvironment analysis. Key presentations include research on liquid biopsies and therapeutic resistance in various cancers. An industry symposium titled 'Leveraging comprehensive genomic data for diagnostic capabilities' will also be featured on November 12.

Personalis, Inc. (Nasdaq: PSNL) reported a 12% increase in third-quarter revenue, totaling $22.3 million compared to $19.8 million in 2020. The company achieved record revenue of $8.6 million from biopharma clients, a 50% growth. New orders for cancer genomic testing exceeded quarterly revenue by three times. Notably, Personalis secured a $10 million contract with the VA Million Veteran Program. Despite these gains, the net loss rose to $17.7 million, worsening from a $9.5 million loss in the previous year. The fourth quarter outlook anticipates revenue between $20.2 million and $20.4 million.

Personalis, Inc. (NASDAQ: PSNL) has expanded its NeXT Platform, enhancing its ability to analyze tumor-immune interactions crucial for cancer therapy responses. Key new features include InfiltrateID™, which identifies immune cell populations; RepertoireID™, which characterizes B-cell receptors; and SHERPA™, an advanced neoantigen prediction algorithm. These improvements aim to facilitate better patient stratification in cancer treatments. Personalis continues to be a leader in advanced genomics, operating a significant sequencing operation and focusing on comprehensive genomic tumor profiling.

Personalis, Inc. (NASDAQ: PSNL) announced the issuance of two significant US patents on October 12 and 26, 2021, related to its NeXT Liquid Biopsy platform. The first patent, US Patent No. 11,142,802, focuses on methods for identifying cancer mutations in cell-free nucleic acids, especially beneficial for early-stage cancer patients. The second patent, US Patent No. 11,155,867, details a deep sequencing method for analyzing exomes from cell-free samples. Combined, these patents enhance Personalis' intellectual property portfolio, supporting advancements in cancer detection and treatment.

Personalis, Inc. (Nasdaq: PSNL) announced the publication of its study on the SHERPA™ algorithm, significantly improving MHC-peptide binding prediction for neoantigen discovery. This new machine learning tool demonstrates a 1.44-fold increase in positive predictive value over existing tools, trained on a dataset of 2.15 million peptides across 167 HLA alleles. The study emphasizes SHERPA's potential in enhancing cancer therapy prediction and accelerating the development of personalized treatments, leveraging data from diverse cell lines.